Your session is about to expire
← Back to Search
Abemaciclib + Abiraterone for Prostate Cancer (CYCLONE 3 Trial)
CYCLONE 3 Trial Summary
This trial is testing whether abemaciclib, when added to abiraterone plus prednisone, can help to treat prostate cancer by prolonging the time before the cancer gets worse.
CYCLONE 3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCYCLONE 3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 132 Patients • NCT02102490CYCLONE 3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.My cancer is prostate adenocarcinoma.I have a history of heart-related fainting, irregular heartbeats, or sudden cardiac arrest but stable atrial arrhythmia is well-controlled with medication.My brain metastases have been treated and stable for 8 weeks, and I haven't taken corticosteroids for 2 weeks.I have started hormone therapy for my cancer and will continue it during the study.My prostate cancer has spread and my testosterone levels are very low.I have not had a heart attack or severe heart issues in the last 6 months.I have a serious liver condition.My organs are working well.I started hormone therapy for my cancer before joining this study.My organs are working well.I have not taken abemaciclib or similar medications before.My prostate cancer is mainly adenocarcinoma.My prostate cancer has spread to 4 or more bones or to my organs.I am fully active or can carry out light work.I have only received hormone therapy for my metastatic prostate cancer.I have 4 or more bone metastases and/or at least 1 visceral metastasis.My high blood pressure is not under control.
- Group 1: Abemaciclib + Abiraterone + Prednisone/Prednisolone
- Group 2: Placebo + Abiraterone + Prednisone/Prednisolone
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the standing of Abemaciclib with the FDA?
"Abemaciclib's safety is estimated to be a 3. Phase 3 trials have some data supporting efficacy and multiple rounds of data supporting safety."
Where can potential participants find this clinical trial?
"There are 78 locations associated with this trial, but a few notable locations are Texas Oncology - Carrollton in Carrollton, Texas, Genesis Cancer Center in Hot Springs, Arkansas, and Providence Medical Foundation in Fullerton, California."
Are we still receiving participants for this experiment?
"The clinical trial is recruiting patients at this time, as reflected on clinicaltrials.gov. This specific trial was first posted on April 14th, 2022 and received its most recent update on October 19th, 2022."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger